Morphic to Participate in Jefferies Global Healthcare Conference

5/31/24 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MORF alert in real time by email

WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will take part in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5^th, at 10:30 AM ET.

A live webcast of the panel discussion and fireside chat at the Jefferies Global Healthcare Conference will be available on the Investor section of Morphic's website at www.morphictx.com. An archived replay will be available on the company's website following the conference.

About Morphic Therapeutic

Morphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company's unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Contacts

Morphic Therapeutic

Chris Erdman

[email protected]

617.686.1718

Get the next $MORF alert in real time by email

Date	Price Target	Rating	Analyst
12/8/2023	$46.00	Buy	Citigroup
9/25/2023	$61.00 → $33.00	Hold	Stifel
9/25/2023		Buy → Neutral	BTIG Research
8/9/2023	$69.00 → $61.00	Buy → Hold	Stifel
9/7/2022	$44.00	Buy	Stifel
7/20/2022	$45.00	Outperform	SVB Leerink
3/31/2022	$68.00	Buy	Canaccord Genuity
2/25/2022	$82.00 → $76.00	Outperform	RBC Capital

Morphic to Participate in Jefferies Global Healthcare Conference

Chat with this insight

Recent Analyst Ratings for
$MORF

$MORF
SEC Filings

SEC Form 15-12G filed by Morphic Holding Inc.

SEC Form S-8 POS filed by Morphic Holding Inc.

SEC Form S-8 POS filed by Morphic Holding Inc.

$MORF
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Citigroup initiated coverage on Morphic with a new price target

Stifel reiterated coverage on Morphic with a new price target

Morphic downgraded by BTIG Research

$MORF
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Edwards Martin bought $48,803 worth of shares (2,376 units at $20.54) (SEC Form 4)

Slattery Joseph P bought $49,436 worth of shares (2,400 units at $20.60), increasing direct ownership by 36% to 9,066 units (SEC Form 4)

Morphic to Participate in Jefferies Global Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $MORF

$MORF SEC Filings

SEC Form 15-12G filed by Morphic Holding Inc.

SEC Form S-8 POS filed by Morphic Holding Inc.

SEC Form S-8 POS filed by Morphic Holding Inc.

$MORF Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Citigroup initiated coverage on Morphic with a new price target

Stifel reiterated coverage on Morphic with a new price target

Morphic downgraded by BTIG Research

$MORF Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Edwards Martin bought $48,803 worth of shares (2,376 units at $20.54) (SEC Form 4)

Slattery Joseph P bought $49,436 worth of shares (2,400 units at $20.60), increasing direct ownership by 36% to 9,066 units (SEC Form 4)

Recent Analyst Ratings for
$MORF

$MORF
SEC Filings

$MORF
Analyst Ratings

$MORF
Insider Purchases